COMPASS Pathways Plc - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing covers the unaudited interim condensed consolidated financial statements for the three and nine months ended September 30, 2020. COMPASS Pathways Plc is a clinical-stage mental health care company developing psilocybin therapy (COMP360) for treatment-resistant depression. The period includes the company's Initial Public Offering (IPO) completed on September 22, 2020, and a corporate reorganization.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2020 | Nine Months Ended Sep 30, 2020 | As of Sep 30, 2020 |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(16.7) million | $(41.5) million | N/A |
| Operating Expenses | $13.5 million | $39.9 million | N/A |
| Cash and Cash Equivalents | N/A | N/A | $196.5 million |
| Accumulated Deficit | N/A | N/A | $(79.1) million |
| Debt | N/A | N/A | $0 (Convertible notes converted) |
Note: All figures in millions unless otherwise stated. The company has no revenue and operates at a loss.
Material Changes vs. Prior Period
- Capital Raise: The company raised approximately $132.9 million in net proceeds from its IPO and $61.3 million from a Series B convertible preferred share issuance in the nine months ended September 30, 2020. This increased cash balances from $25.0 million (Dec 31, 2019) to $196.5 million.
- Expense Growth: Total operating expenses increased significantly to $39.9 million for the nine months ended September 30, 2020, compared to $13.9 million in the prior year period. This was driven by increased clinical trial costs and a $16.6 million non-cash share-based compensation expense (compared to $2.5 million in 2019), largely due to accelerated vesting of options upon the IPO.
- Foreign Exchange: The company recorded a foreign exchange loss of $3.3 million for the nine months ended September 30, 2020, compared to a gain of $0.1 million in the prior year, due to the translation of USD cash balances against the GBP functional currency.
- Debt Elimination: Outstanding convertible notes totaling $18.4 million were converted into Series B preferred shares in April 2020, resulting in zero debt on the balance sheet as of September 30, 2020.
Outlook, Risks, and Management Commentary
- Liquidity: Management believes the $196.5 million in cash on hand is sufficient to fund operations and capital expenditures into 2023.
- Development Timeline: The company is conducting a Phase IIb trial for COMP360. Data is expected in late 2021, though the timeline has been delayed due to the COVID-19 pandemic impacting patient enrollment.
- Risks: Key risks include the inability to raise additional capital, delays in clinical trials due to the pandemic, regulatory hurdles for psilocybin (a controlled substance), and the uncertainty of commercialization. The company expects to continue incurring significant losses for the foreseeable future.
- Unusual Items: The financial results include significant non-cash charges related to share-based compensation ($16.6 million for the nine months) and foreign exchange losses ($3.3 million for the nine months) which impacted the net loss but did not affect cash flow from operations to the same degree.
Investor Verification Checklist
- Cash Runway: Verify the $196.5 million cash balance and the assumption that it will last into 2023 given the high burn rate.
- Share-Based Compensation: Review the $16.6 million non-cash expense to understand the impact of accelerated vesting on future dilution and expense recognition.
- Clinical Trial Progress: Monitor enrollment rates for the Phase IIb trial and the impact of COVID-19 on the late 2021 data readout.
- Regulatory Status: Track the scheduling status of psilocybin with the DEA and other regulatory bodies, as this is critical for commercialization.
- Foreign Exchange Exposure: Assess the company's strategy for managing currency risk given the functional currency (GBP) vs. reporting currency (USD) mismatch.